Table 3 Temperature analyses and outcomes of included patients, according to the methods of cooling. Data are expressed as count (%) or median (25th–75th percentiles)
IC (n = 218) | SFC (n = 134) | |
|---|---|---|
Primary outcome | ||
CPC 3–5 at 6 months | 69 (32%) | 51 (38%) |
Secondary outcomes | ||
Mortality at 6 months | 65 (29%) | 43 (32%) |
Adverse events | ||
Any adverse event | 203 (93%) | 118 (88%) |
Pneumonia | 106 (49%) | 56 (42%) |
Other infections | 75 (34%) | 54 (40%) |
Any bleeding | 24 (11%) | 16 (12%) |
RBC transfusion | 20 (9%) | 15 (11%) |
Seizure/myoclonus localized | 27 (12%) | 18 (13%) |
Seizure/myoclonus globalized | 39 (18%) | 25 (19%) |
Severe circulation failure | 13 (6%) | 15 (11%)€ |
Arrhythmias | 105 (48%) | 50 (37%)* |
Severe (VT/VF or unstable despite treatment) | 21 (10%) | 19 (14%) |
New cardiac arrest requiring CPR | 7 (3%) | 5 (4%) |
Renal replacement therapy | 13 (6%) | 14 (10%) |
Hyperglycemia | 169 (78%) | 113 (83%) |
Hypernatremia | 21 (10%) | 24 (18%)* |
Hypokalemia | 88 (40%) | 38 (28%)* |
Resource use | ||
ICU length of stay (days) | 5 [3–7] | 6 [3–9] |